UPPSALA, Sweden, March 4 /PRNewswire/ -- DOXA AB, a Swedish biomaterials firm, announced today that it has treated its first patient utilizing its revolutionary high strength, bioactive ceramic material, which upon application, results in a complete chemical integration between the material and bone within a matter of moments. Surgeons at Akademiska University hospital in Uppsala repaired a distal radius fracture through minimally invasive injection of the DOXA material.
"The first clinical use of our material in orthopaedics represents the culmination of years of work, and a significant milestone for DOXA," commented Peter Bramberg, President and Chief Executive Officer. "These clinical trials will validate that the DOXA technology will effectively address the issues of concern with the current generation of biomaterials, and set the standard for the next."
DOXA has developed a platform of materials having superior strength, variable handling characteristics and programmable properties. The company plans to begin clinical trials for vertebral compression fractures in March, and has targeted numerous other orthopaedic and spinal applications.
DOXA AB is a privately held company focused on commercialization of next generation biomaterials, the properties of which are engineered for specific applications. Its extensive patent portfolio provides it exclusive use of a broad class of materials having extraordinary biomechanical and biochemical properties.
For more information contact:
Axel Johanssons gata 4-7
SE-75451 Uppsala, Sweden
Web address http://www.doxa.se/ /
CONTACT: Peter Bramberg of DOXA AB, +46706673100, firstname.lastname@example.org